Shire PLC (SHPG)

175.75
0.93 0.53
NASDAQ : Health Care
Prev Close 176.68
Open 176.63
Day Low/High 175.57 / 177.97
52 Wk Low/High 147.60 / 270.63
Volume 926.26K
Avg Volume 987.60K
Exchange NASDAQ
Shares Outstanding 302.23M
Market Cap 53.11B
EPS 1.30
P/E Ratio 47.75
Div & Yield 1.54 (0.90%)

Latest News

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire launches campaign to raise global awareness during World PI Week

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

European Stocks Mixed as Frankfurt Rises, Paris Falls

European Stocks Mixed as Frankfurt Rises, Paris Falls

The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients

Everything We Know About BioCryst's New HAE Drug

Everything We Know About BioCryst's New HAE Drug

BioCryst's Hereditary angioedema drug-trial results not compelling.

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Also up early Thursday: Bellicum and Novocure.

Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

New Data From Shire Aim To Help Close The Diagnosis And Treatment Gap For People With Hemophilia

New Data From Shire Aim To Help Close The Diagnosis And Treatment Gap For People With Hemophilia

Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care

5 Toxic Stocks to Avoid

5 Toxic Stocks to Avoid

Here's a look at five 'toxic stocks' to sell.

Why Shire, Great Plains, GE Are Waving Red Flags

Why Shire, Great Plains, GE Are Waving Red Flags

The charts of these and two other big stocks are flashing warning signs at investors.

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.